No Data
Shanghai Fosun Pharmaceutical Advances Henlius Merger Plans
Zhitong Hong Kong stocks early knowledge | The Ministry of Commerce accelerates the introduction of policy documents to promote the initial public offering economy. In November, the total electricity consumption increased by 2.8% year-on-year.
The spokesperson of the Ministry of Commerce stated that the ministry will implement policies to promote the high-quality development of service Consumer, continuously enrich the supply of service Consumer, and innovate diversified Consumer scenarios.
Focusing on autoimmune diseases, HENLIUS is collaborating with Palleon to advance glyco-editing therapies.
Shanghai and Waltham, Massachusetts, December 19, 2024—HENLIUS (2696.HK) and Palleon Pharmaceuticals Inc. (‘Palleon’) announced the signing of a cooperation and licensing agreement to develop and commercialize Palleon's first-in-class human sialidase fusion protein E-602 in combination with HENLIUS's independently developed Hanlikang (rituximab) for the treatment of autoimmune diseases including lupus nephritis (LN). Palleon is a leading company.
Palleon Pharmaceuticals and Henlius Collaborate to Advance Glycan Editing as a Treatment for Autoimmune Diseases
Shanghai Henlius Partners With Palleon for Global Drug Development
HENLIUS (02696): A cooperation and licensing agreement has been established with PALLEON regarding E-602 and combination therapy.
HENLIUS (02696) announced that on December 19, 2024, the company entered into an agreement with Palleon P...
No Data
